Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 372.30K | 205.80K | 147.90K | 194.90K | 96.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 372.30K | 205.80K | 147.90K | 194.90K | 96.10K |
| Cost of Revenue | 126.70K | 16.40K | 25.00K | 24.80K | 6.80K |
| Gross Profit | 245.60K | 189.30K | 122.90K | 170.10K | 89.30K |
| SG&A Expenses | 533.70K | 359.00K | 306.30K | 349.50K | 361.70K |
| Depreciation & Amortization | 21.80K | 21.80K | 21.30K | 21.30K | 20.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 714.70K | 427.00K | 382.00K | 428.30K | 443.60K |
| Operating Income | -342.40K | -221.20K | -234.10K | -233.40K | -347.50K |
| Income Before Tax | -362.50K | -247.60K | -293.50K | -263.30K | -372.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -362.50K | -247.60K | -293.50K | -263.30K | -372.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -362.50K | -247.60K | -293.50K | -263.30K | -372.90K |
| EBIT | -342.40K | -221.20K | -234.10K | -233.40K | -347.50K |
| EBITDA | -332.30K | -211.20K | -224.30K | -223.80K | -326.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 109.04M | 108.89M | 108.01M | 99.06M | 105.28M |
| Average Diluted Shares Outstanding | 109.04M | 108.89M | 108.01M | 99.06M | 105.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |